The 36-month beta value for ONCY is also noteworthy at 1.30. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 5 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ONCY is 75.99M, and at present, short sellers hold a 3.49% of that float. The average trading volume of ONCY on December 24, 2024 was 561.69K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ONCY) stock’s latest price update
Oncolytics Biotech, Inc (NASDAQ: ONCY)’s stock price has plunge by 4.38relation to previous closing price of 0.91. Nevertheless, the company has seen a 22.63% surge in its stock price over the last five trading sessions. prnewswire.com reported 2024-12-23 that Promising BRACELET-1 results in HR+/HER2- metastatic breast cancer lay the foundation for potential registration-enabling study and accelerated approval Advancing gastrointestinal cancer pipeline underscores potential for additional registration-enabling studies SAN DIEGO and CALGARY, AB, Dec. 23, 2024 /PRNewswire/ — Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, is providing a recap of the major accomplishments from 2024 and a preview of the milestones that are expected over the next 12 months. Following the promising BRACELET-1 readout, Oncolytics expects additional data readouts across our clinical development program in 2025, forming what it believes is a clear pathway to future commercialization opportunities.
ONCY’s Market Performance
ONCY’s stock has risen by 22.63% in the past week, with a monthly drop of -0.90% and a quarterly rise of 5.09%. The volatility ratio for the week is 15.00% while the volatility levels for the last 30 days are 7.44% for Oncolytics Biotech, Inc The simple moving average for the last 20 days is 8.79% for ONCY stock, with a simple moving average of -8.88% for the last 200 days.
Analysts’ Opinion of ONCY
Many brokerage firms have already submitted their reports for ONCY stocks, with Maxim Group repeating the rating for ONCY by listing it as a “Buy.” The predicted price for ONCY in the upcoming period, according to Maxim Group is $3 based on the research report published on October 06, 2022 of the previous year 2022.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ONCY reach a price target of $15. The rating they have provided for ONCY stocks is “Buy” according to the report published on February 17th, 2021.
ONCY Trading at -7.98% from the 50-Day Moving Average
After a stumble in the market that brought ONCY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.20% of loss for the given period.
Volatility was left at 7.44%, however, over the last 30 days, the volatility rate increased by 15.00%, as shares sank -3.20% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.30% lower at present.
During the last 5 trading sessions, ONCY rose by +17.39%, which changed the moving average for the period of 200-days by -14.61% in comparison to the 20-day moving average, which settled at $0.8669. In addition, Oncolytics Biotech, Inc saw -29.96% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ONCY
The total capital return value is set at -2.13. Equity return is now at value -144.22, with -78.05 for asset returns.
Currently, EBITDA for the company is -33.71 million with net debt to EBITDA at 0.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.99.
Conclusion
In summary, Oncolytics Biotech, Inc (ONCY) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
